Tauroursodeoxycholate-d4 (sodium)

• Description :

  Tauroursodeoxycholate-d4 (sodium) is the deuterium labeled Tauroursodeoxycholate sodium. Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

• Product Name Alternative :

  Tauroursodeoxycholic acid-d4 (sodium) ; TUDCA-d4 (sodium) ; UR 906-d4 (sodium)

• UNSPSC :

  12352211

• Target :

  Apoptosis; Caspase; Endogenous Metabolite; ERK; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/Wnt

• Field of Research :

  Cancer

• Purity :

  99.50

• Solubility :

  DMF : ≥ 25mg/mL|DMSO : ≥ 20mg/mL|Ethanol : ≥ 1mg/mL

• Smiles :

  C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C([2H])([2H])[C@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])CC[C@]12C

• Molecular Formula :

  C26H40D4NNaO6S

• Molecular Weight :

  525.71

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92 (2) :307-16.|[3]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53 (3) :337-345.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [2410279-95-5]